Forbes December 8, 2023
Updated, Dec. 8: The Food and Drug Administration on Friday approved the first drug to treat patients with sickle cell disease using the Nobel Prize-winning CRISPR gene-editing therapy. Casgevy (also known as Exa-cel) is manufactured by Vertex Pharmaceuticals in Boston and CRISPR Therapeutics in Zug, Switzerland. The FDA also approved a conventional sickle cell disease treatment called Lyfgenia, by Bluebird Bio in Somerville, Massachusetts. This article was originally published on Dec. 5 and updated after news of the FDA’s announcement.
Victoria Gray never remembers a moment when she didn’t have sickle cell disease. She was diagnosed with the condition at 3 months of age after she cried so hard during a bath that she was taken to the emergency room....
Today's Sponsors
Today's Sponsor